ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial
Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL), …
Post
-
-
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
Pfizer’s Braftovi (encorafenib) combination therapy was shown to reduce the risk of death by nearly half compared to standard of …
-
EyePoint advances with Duravyu Phase III trial
EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for …
-
Alvotech and Advanz to commercialise biosimilars in Europe
Alvotech and UK-based Advanz Pharma have broadened their commercial collaboration with an agreement to include three additional biosimilar candidates for …
-
FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review
The US Food and Drug Administration (FDA) has rejected Stealth BioTherapeutics’ elamipretide for the treatment of Barth syndrome after a …
-
Astellas and Evopoint sign ADC licensing deal
Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a Claudin18.2 (CLDN18.2)-targeting clinical-stage antibody-drug conjugate (ADC). Astellas …
-
Daiichi Sankyo and MSD withdraw US BLA for lung cancer treatment
Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed DXd antibody …
-
HHS cancels $766m bird flu vaccine contract with Moderna
The US Department of Health and Human Services (HSS) has terminated a contract previously awarded to Moderna to help advance …
-
The impact of drug pricing and reimbursement on the pharmaceutical industry
A recent survey for GlobalData’s “State of the Biopharmaceutical Industry 2025” report, conducted at the end of 2024, found drug …
-
Solid tumours: CAR-T therapies’ Waterloo
CAR-Ts are revolutionising the treatment of blood cancers such as B-cell acute lymphocytic leukaemia. However, their success has not yet …
-
Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities
US-based Telesis Bio has announced a licensing agreement with Regeneron Pharmaceuticals, enabling the latter to deploy the Gibson SOLA platform …
-
iTeos to shut down following $2bn GSK-partnered TIGIT asset failure
Just two weeks after dropping a TIGIT candidate jointly developed with GSK, iTeos has announced plans to wind down operations …
-
FDA approves Eton’s application for hydrocortisone oral solution
Eton Pharmaceuticals’ new drug application (NDA) for Khindivi, an oral solution of hydrocortisone, has received US Food and Drug Administration …
-
EC approves BMS’ nivolumab SC formulation for solid tumours
The European Commission (EC) has approved the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) with a …
-
ASCO25: Merck KGaA to seek approval of TGCT drug after Phase III success
Merck KGaA (Merck) is filing for global regulatory approvals of its CSF-1R inhibitor pimicotinib after it met the primary and all …
